For a patient waiting on a new prescription, the most critical step often happens after the doctor hits send. It's the prior authorization, a dense administrative hurdle where insurers demand proof of medical necessity before they will cover a drug. Tandem, a New York-based healthtech startup founded in 2023, is betting that this specific, painful bottleneck is where AI can deliver immediate value, by automating the entire medication access workflow from insurance check to pharmacy routing [withtandem.com].
The Wedge in the Workflow
Tandem's platform integrates directly into a provider's electronic health record system. When a prescription is written, its AI takes over the subsequent steps: checking insurance coverage, generating the required documentation, submitting the prior authorization request, managing appeals, searching for copay assistance, and routing the prescription to the optimal pharmacy [Entrepreneurloop, 2026]. The company claims the system requires no intervention from physicians or their staff. Tandem reportedly supports thousands of patients weekly [Pear VC].
A Billion-Dollar Vote of Confidence
Tandem's reported trajectory points to significant investor conviction. The company is said to have raised a $100 million funding round at a $1 billion valuation in 2026 [MENA Fintech Association, 2026]; [Modern Healthcare, 2026]. Its cap table includes Pear VC, BoxGroup, Accel, Lux Capital, Thrive Capital, and General Catalyst.
| Investor | Stage Focus | Notable For |
|---|---|---|
| Accel | Early to Growth | Enterprise software scale-ups |
| Thrive Capital | Growth | Healthcare and fintech |
| Lux Capital | Deep Tech & Science | Frontier technology bets |
| Pear VC | Seed & Series A | Product-centric founders |
| General Catalyst | All Stages | Health assurance transformation |
Navigating a Crowded and Complex Field
Tandem operates in a competitive space with established players like Cohere Health. Tandem says it is free to providers and patients, monetizing through per-prescription fees, subscriptions, or value-based contracts [Modern Healthcare, 2026]. This model aligns incentives but places the burden of proof on Tandem's ability to consistently deliver outcomes across a diverse payer landscape.
The Patient at the End of the Line
For all the talk of automation and valuation, the core patient population here is anyone prescribed a specialty medication or any treatment that triggers an insurer's utilization management protocol. The standard of care today is a fragmented, manual process. Tandem's bet is that by owning this specific, broken workflow, it can make the path from prescription to patient not just faster, but fundamentally more reliable.